Delving into the Latest Updates on NapaJen Pharma, Inc. with Synapse

Overview

Basic Info

Introduction

NapaJen Pharma is a company that focuses on creating innovative drug delivery solutions by leveraging the body's natural cellular transport pathways. Their product line includes a lead platform and various drug delivery options. The company's specialty lies in the development of unique drug delivery systems that utilize these natural transport pathways to move molecular cargo into cells and throughout their internal compartments. Founded in 2004 by Dr. Kazuo Sakurai and Hironori Ando, NapaJen Pharma is headquartered in Burlingame, California.

Tags

Neoplasms

siRNA

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2

Top 5 Drug Type	Count

siRNA	2

Top 5 Target	Count

TLR9(Toll like receptor 9)	2

The CD40/CD154 co-stimulatory pathway is crucial in alloimmune response. We developed a novel small interfering RNA (siRNA) delivery system with a poly-dA extension at the 5'-end of the siRNA sense strand that was stably incorporated into 1,3-β-glucan (schizophyllan, SPG). This was captured and incorporated into dendritic cells (DCs) through its receptor, Dectin-1, specifically silencing CD40 genes (siCD40) to exert immunoregulatory activity. siCD40/SPG-treated CBA mice permanently accepted B10 fully mismatched cardiac allografts. Consistent with graft survival, the infiltration of CD4(+), CD8(+) T cells into the graft was lower, and that the numbers of CD40(low)CD11c(+) DCs cells and CD4(+)Foxp3(+)cells were increased in both the graft and in the recipient spleen. In addition, naive CBA recipients given an adoptive transfer of splenocytes from the primary recipients with siCD40/SPG accepted a heart graft from donor-type B10, but not third-party Balb/c mice. In conclusion, the treatment with siCD40/SPG targeting DCs could generate antigen-specific Tregs, resulting in the permanent acceptance of mouse cardiac allografts. These findings have important implications for clarifying the mechanism underlying the induction of tolerance in DCs, and also highlight the potential of immunomodulation and the feasibility of siRNA-based clinical therapy in the transplantation field.

15 Nov 2008·Bulletin of the Chemical Society of Japan

3′ Poly(dA)-Tailed Thrombin DNA Aptamer to Increase DNase-Resistance and Clotting Inhibitory Activity

Author: Takei, Yoshifumi ; Ando, Hironori ; Uno, Atsushi ; Koyama, Yoshikazu ; Satoh, Susumu ; Shimada, Naohiko ; Sakurai, Kazuo ; Takeda, Yoichi ; Uehara, Shuichiro

AbstractAptamers are an attractive candidate for a molecular-targeted drug since they can show ability to precisely recognize proteins with a large affinity similar to antibodies. A drawback of aptamers is that they can be easily degraded under biological conditions by DNase (or RNase). In this study, we attached poly(dA) tail to the 3′ end of thrombin DNA aptamer and found that its survival time in human plasma was prolonged by about threefold compared to the original aptamers (i.e., without the tail). We found that the attachment of a poly(dA) tail at the 3′ end caused an increase of the clotting inhibitory activity. A preliminary in vivo assay using BALB/c mice confirmed a considerably elongated clotting time for the tailed aptamer. When the poly(dA) tail was attached to three other DNA aptamers, DNase resistance was increased, indicating that the present finding can be universally applied to increase stability of DNA aptamers.

100 Deals associated with NapaJen Pharma, Inc.

Login to view more data

100 Translational Medicine associated with NapaJen Pharma, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

Other

Login to view more data